Cyprus Mail on MSN
Travere wins FSGS approval for FILSPARI, a milestone for holders including Armistice Capital
Travere Therapeutics spent the first half of 2026 converting a single approved medicine into a broader commercial and pipeline story. A rare-disease drugmaker built around FILSPARI, its treatment for ...
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the launch of a new awareness campaign, “Play It Forward,” to bring hope and encouragement to the focal segmental ...
In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on Insmed, with a price target of $207.00. Claim 55% Off TipRanks. Unlock powerful investing tools ...
Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation announce the creation of a new resource for IgA nephropathy patients and their loved ones: the IgA nephropathy patient ...
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm ...
Using a continuous glucose monitor improved time in range with no increase in hypoglycemia for people with type 2 diabetes ...
With its focus on small-cap companies and exposure to China, The Biotech Growth Trust (BIOG) is one such example. Over the past year, the trust’s total shareholder return was 105 per cent – double the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results